EGFR and non-small cell lung carcinoma: Moreover, it has been shown that EGFR‐mutant NSCLC cells tolerated to short‐term EGFR‐TKI treatment possess elevated Mcl‐1 levels and can be sensitized to EGFR‐TKIs by targeting Mcl‐1 (Song et al., 2018).